Previous reports have indicated that pyrimethamine could activate CD8+ T lymphocytes in breast cancer, and some reports have shown that restoring p53 activity can enhance CD8+ T-cell antitumor immunity [19, 20]. This evidence concerns the gene CD8A and breast carcinoma.